从资金流向上来看，当日生物制品板块主力资金净流入3.99亿元，游资资金净流出6286.66万元，散户资 金净流出3.36亿元。生物制品板块个股资金流向见下表： 证券之星消息，1月13日生物制品板块较上一交易日上涨1.15%，康乐卫士领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920575 | 康乐卫士 | 11.99 | 29.90% | 35.12万 | | 4.02亿 | | 688331 | 荣昌生物 | 114.46 | 20.00% | 21.22万 | | 23.69亿 | | 688137 | 沂岸蛋白 | 49.60 | 15.43% | 5.81万 | | 2.91亿 | | 920344 | 三元基因 | 28.45 | 11.44% | 6.86万 | | 1.94亿 | | 301047 | 义翘神州 | 82.02 | ...

格隆汇1月13日｜中信建投证券研报指出，荣昌生物与艾伯维就RC148（PD1/VEGF）实现全球合作，整 体交易的首付款为6.5亿美元，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，同时 还拥有在大中华地区以外的净销售额的两位数分级特许权使用费，首付款和总金额超出市场预期。具体 来看，RC148此前在1L NSCLC和后线NSCLC中均展现出优异临床数据，药物目前在多个实体瘤中开展 临床研究，未来可期。认为本次合作让公司的国际化得到进一步加强，看好公司未来发展。预计2025- 2027年，公司收入分别为24.55亿元、33.88亿元和45.74亿元，维持"买入"评级。（暂不考虑BD的收入 确认影响） ...

Group 1 - The CRO and innovative drug sectors are experiencing strong gains, with stocks like Rongchang Biopharma A-shares and H-shares, WuXi AppTec, and Sanofi rising by 17%, 9%, 7.9%, and 7.2% respectively, leading to a 3.5% increase in the Tianhong Innovative Drug ETF [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50 Index, focusing on 50 actively traded innovative drug and CXO companies with high R&D investment [1] - The ETF has seen a net inflow of 207 million yuan over the past five days, indicating strong investor interest [1] Group 2 - The 44th JPMorgan Global Healthcare Conference is set to take place, with over 20 domestic innovative drug companies confirmed to participate, including WuXi AppTec and several others [1] - WuXi AppTec is projected to achieve a profit of 19.151 billion yuan in 2025, representing a year-on-year increase of 103%, with Q4 net profit expected to reach 7.075 billion yuan, a quarter-on-quarter increase of 101% [1] - The sixth batch of national centralized procurement for high-value medical consumables is about to open for bidding, including 12 types of medical consumables [2] Group 3 - The medical device ETF (159873) has a significant focus on brain-machine interfaces, accounting for over 19% of its composition, indicating strong technological attributes [2] - The ETF's components include a high proportion of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market, nearly 80%, suggesting a robust growth potential [2] - The industry outlook for 2026 remains positive, with a focus on innovation, international expansion, and recovery in challenging markets, particularly in the CXO and upstream supply chain sectors [2]

数据宝统计，截至14:22，荣昌生物成交额21.94亿元，创上市以来新高。最新股价上涨19.66%，换手率 12.14%。上一交易日该股全天成交额为6.60亿元。（数据宝） （文章来源：证券时报网） ...

Core Viewpoint - Rongchang Biologics has signed an exclusive licensing agreement with AbbVie for its novel PD-1/VEGF bispecific antibody drug RC148, which is expected to enhance the immune system's anti-tumor activity by targeting both PD-1 and VEGF pathways [1][2] Group 1: Financial Aspects - Rongchang Biologics will receive an upfront payment of $650 million and may earn up to $4.95 billion in milestone payments based on the achievement of development, regulatory, and commercialization milestones [2] - The company will also receive a tiered royalty on net sales achieved by AbbVie outside of Greater China [2] - In the first three quarters of 2025, Rongchang Biologics reported total revenue of 1.72 billion yuan, a year-on-year increase of 42.27% [3] Group 2: Product and Development - RC148 is designed to activate anti-tumor immune responses while inhibiting tumor-driven angiogenesis, and is currently undergoing clinical studies for various advanced malignant solid tumors in China [1][3] - This collaboration marks another significant step in Rongchang Biologics' international strategy, following previous partnerships for its core products [3] Group 3: Strategic Implications - The partnership with AbbVie is seen as a crucial move for Rongchang Biologics to leverage international pharmaceutical resources for global product development [3] - AbbVie’s extensive experience in global clinical development and commercialization in oncology is expected to support the overseas launch of RC148 [3] - The cash flow generated from this deal will further bolster Rongchang Biologics' R&D funding, ensuring the development of its pipeline products [3]

Investment Rating - The investment rating for Rongchang Biologics (688331) is "Buy" (maintained) [2] Core Insights - On January 12, 2026, Rongchang Biologics announced an exclusive licensing agreement with AbbVie for its self-developed PD-1/VEGF bispecific antibody drug RC148. AbbVie will receive exclusive rights for development, production, and commercialization outside Greater China, with an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with double-digit royalties on net sales outside Greater China [5][11] - The deal is seen as a significant entry into the business development (BD) market for 2026, highlighting the growing trend of large licensing transactions in the PD-1/VEGF space, which is crucial for next-generation cancer immunotherapy [6] - AbbVie, a well-established player in oncology, aims to enhance treatment standards for patients with difficult-to-treat cancers, and the acquisition of RC148 will further strengthen its pipeline in immuno-oncology [7] Financial Projections - Revenue projections for Rongchang Biologics are adjusted to 2.25 billion, 7.42 billion, and 3.98 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 31.1%, 229.6%, and -46.3% [11] - The net profit attributable to the parent company is expected to be -763 million, 3.19 billion, and 220 million yuan for the same years, with growth rates of 48.0%, 517.8%, and -93.1% [11] - The gross margin is projected to remain stable, increasing from 80.4% in 2024 to 82.2% in 2027 [13]

昨天联手大涨的商业航天和AI应用板块，今天上午，两者走势"分道扬镳"。 商业航天板块大幅波动，在早盘的前7分钟，板块持续下跌，中国卫通、航天发展、航天机电等多只人气股直线跌停。10:35之后，商业航天板块迎来修 复，临近上午收盘，板块拉升，跌幅收窄。 AI应用继续上涨，其中，"AI+制药""AI+医疗"方向走势最强。迪安诊断、中文在线、天龙集团等个股大涨。 此外，保险、油气开采、锂矿等板块上涨。截至上午收盘，上证指数下跌0.03%，深证成指下跌0.31%，创业板指下跌0.83%。 | 医药股大涨 | | --- | | 今天上午，医药股大涨，医疗服务、生物制品等板块涨幅居前。 | | 迪安诊断 | 31.27 | 19.99% | 157亿 | | --- | --- | --- | --- | | 融 300244 | | | | | 3天3板 最终涨停09:35 | | | | | 兰卫医学 | 13.28 | 19.96% | 47.8 Z | | 融 301060 | | | | | 首板涨停 最终涨停 09:55 | | | | | 博深失药 | 12.92 | 19.96% | 36.3 Z | ...

上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限量发放！先到先得！ 昨天联手大涨的商业航天和AI应用板块，今天上午，两者走势"分道扬镳"。 商业航天板块大幅波动，在早盘的前7分钟，板块持续下跌，中国卫通、航天发展、航天机电等多 只人气股直线跌停。10:35之后，商业航天板块迎来修复，临近上午收盘，板块拉升，跌幅收窄。 AI应用继续上涨，其中，"AI+制药""AI+医疗"方向走势最强。迪安诊断、中文在线、天龙集团等个 股大涨。 此外，保险、油气开采、锂矿等板块上涨。截至上午收盘，上证指数下跌0.03%，深证成指下跌 0.31%，创业板指下跌0.83%。 医药股大涨 今天上午，医药股大涨，医疗服务、生物制品等板块涨幅居前。 | 成分股 星金 | 简况(F10) | 资金 | 板块分? | | --- | --- | --- | --- | | 名称代码 | 最新 | 涨幅 ◆ | 流通市值 | | 诺思格 | 76.48 | 20.01% | 43.7 Z | | 融 301333 | | | | | 首板涨停 最终涨停 10:07 | | | | | 涨博医药 | 56.64 | 20. ...

Group 1: Fixed Income Market Insights - In the second week of January, the real estate sector showed a significant decline in new home heat, while second-hand homes saw a slight increase, remaining below last year's levels, indicating a need for price improvement [2] - Industrial production showed a widening year-on-year decline in freight volume, with a mixed performance in production rates across sectors, particularly in coking and chemicals, while construction materials like cement showed a slight narrowing in supply-demand decline [2] - External demand indicators showed a year-on-year decline in throughput, but continued resilience in exports to South Korea and Vietnam, while consumer demand for travel and automotive purchases showed signs of recovery [2] Group 2: Real Estate Sector Analysis - The Hong Kong real estate market is experiencing a recovery, with November housing prices continuing to rise, and December private residential transaction volumes significantly increasing year-on-year, reaching a twenty-year high for new home sales [6] - Retail sales in Hong Kong showed a rebound, with November retail rental declines significantly narrowing, indicating a positive trend for commercial real estate [6] - The report recommends focusing on Hong Kong-listed property companies, particularly New World Development and Link REIT, which are expected to benefit from the ongoing recovery in the market [6] Group 3: Electric Power Equipment and New Energy - The adjustment of export tax rebates for battery products is expected to lead to a short-term surge in battery exports, intensifying supply-demand tensions in lithium and related sectors, while long-term effects may favor companies with overseas production capabilities [7] - Recommended companies include CATL, EVE Energy, and others, which are well-positioned to benefit from the changing landscape in the battery industry [7] Group 4: Nonferrous Metals Sector - The report indicates that profits in the electrolytic aluminum sector are expected to rise in the first half of 2026, driven by a tightening supply-demand balance despite current weak downstream purchasing sentiment [8] - The anticipated seasonal demand in the "golden three silver four" months is expected to support aluminum prices and profit margins [8] Group 5: Technology Sector Developments - NVIDIA's acquisition of Groq is highlighted as a significant strategic move, emphasizing the importance of low-latency inference technology in the evolving AI landscape [9] - This acquisition is expected to enhance NVIDIA's capabilities in the Agentic AI sector, aligning with industry trends towards more responsive AI systems [9] Group 6: Semiconductor Industry Insights - The report discusses the increasing capital expenditure in the semiconductor cleanroom sector, driven by the demand for advanced manufacturing processes, with expectations of significant growth in the global semiconductor market [11] - Companies involved in cleanroom construction are expected to see improved profitability due to the high demand and limited supply of skilled labor in overseas markets [11] Group 7: Key Company Recommendations - Junwei Electronics is recommended for a buy rating, with a target price of 42.1 yuan, as it transitions from a precision resistor leader to a comprehensive current detection solution provider [12] - The report also highlights the potential of WeRide, with a buy rating and target prices set for both Hong Kong and US markets, due to its dual focus on domestic and international markets for autonomous driving [13]

Market Overview - On January 13, A-shares opened higher but showed mixed performance by midday, with the Shanghai Composite Index down 0.03%, Shenzhen Component Index down 0.31%, and ChiNext Index down 0.83% [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 2.44 trillion yuan, an increase of 128.3 billion yuan compared to the previous trading day [1] Sector Performance AI Application Sector - The AI application concept continued to show strength, with over ten constituent stocks hitting the daily limit, including Ingrity Media, Liou Co., and Shengguang Group [1] - AI medical stocks were notably active, with companies like Meian Health and Dean Diagnostics achieving three consecutive daily limits, and Hongbo Pharmaceutical hitting a 20% limit up [1][9] Commercial Aerospace Sector - The commercial aerospace sector experienced a significant pullback after a period of rapid growth, with multiple stocks showing declines of over 10% [6][7] - Notable declines included Aerospace Huanyu down 19.58%, Guolian Aviation down 14.32%, and Sry New Materials down 14.29% [6] Lithium Mining Sector - The lithium mining sector saw a resurgence, with stocks like Tibet Summit hitting the daily limit up, and others like Salt Lake Shares and Ganfeng Lithium rising over 7% [14] - The price of lithium carbonate futures surpassed 170,000 yuan per ton, marking a rise of over 9% and reaching a new high since October 2023 [14] Precious Metals Sector - The precious metals sector experienced a rally, with spot gold prices reaching a record high of $4,630.28 per ounce [17] - Stocks such as Hunan Silver and Xiaocheng Technology saw significant gains, both exceeding 8% [17] Expert Insights - Experts have raised warnings about the speculative nature of the commercial aerospace sector, emphasizing the need for companies to disclose key information to reduce information asymmetry risks [7] - The commercial aerospace sector is currently transitioning from policy incubation to large-scale implementation, with challenges such as low satellite data utilization and a lack of sustainable profit models in the consumer market [7]